Have a personal or library account? Click to login
Upregulation of FOXP3+ Regulatory T Lymphocytes and CD8+ Lymphocytes in Patients with High-Grade Squamous Intraepithelial Lesions Correlated with HPV Infection Cover

Upregulation of FOXP3+ Regulatory T Lymphocytes and CD8+ Lymphocytes in Patients with High-Grade Squamous Intraepithelial Lesions Correlated with HPV Infection

Open Access
|Jun 2022

References

  1. Bedell, S. L., Goldstein, L. S., Goldstein, A. R., Goldstein, A. T. (2020). Cervical cancer screening: Past, present, and future. Sex Med., 8 (1), 28–37.10.1016/j.sxmr.2019.09.00531791846
  2. Bedoya, A. M., Jaramillo. R., Baena, A., Castano, J., Olaya, N., Zea, A. H., Herrero, R., Sanchez, G. I. (2013). Location and density of immune cells in precursor lesions and cervical cancer. Cancer Microenviron., 6 (1), 69–77.10.1007/s12307-012-0097-8360121522290207
  3. Brenton, J. D., Ellenson, L. H., Gilks, C. B., Herrington, C. S. (2019). WHO Classification of Tumours. 5th edition. Vol. 4. WHO. Lyon, 632 pp.
  4. Brito, M. J., Sequeira, P., Silva, I., Quintas, A., Martins, C., Félix, A. (2021). CD4 + and CD8 + cell populations in HIV-positive women with cervical squamous intra-epithelial lesions and squamous cell carcinoma. Int. J. Infect. Dis., 103, 370–377.10.1016/j.ijid.2020.10.08333157285
  5. Bonin, C. M., Padovani, C. T. J., da Costa, I. P, Ávila, L. S., Ferreira, A. M. T., Fernandes, C. E. S., Dos Santos, A. R., Tozetti, I. A. (2018). Detection of regulatory T cell phenotypic markers and cytokines in patients with human papillomavirus infection, J. Med. Virol., 91, 2, 317–325.10.1002/jmv.25312
  6. Das, D., Sarkar, B., Mukhopadhyay, S., Banerjee, C., Biswas, S. M. (2018). An altered ratio of CD4+ and CD8+ T lymphocytes in cervical cancer tissues and peripheral blood — a prognostic clue? Asian Pac. J. Cancer Prev., 19 (2), 471.
  7. Gholami, D. M., Kardar, G. A., Saeedi, Y., Heydari, S., Garssen, J., Falak, R. (2017). Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. Cell Immunol., 322,1–14.10.1016/j.cellimm.2017.10.00229079339
  8. Gurrola-Diaz, C. M., Suarez-Rincon, A. E., Vazquez-Camacho, G., Buonocunto-Vazquez, G., Rosales-Quintana, S., Wentzensen, N., von Knebel Doeberitz, M. (2008). P16INK4a immunohistochemistry improves the reproducibility of the histological diagnosis of cervical intraepithelial neoplasia in cone biopsies. Gynecol. Oncol., 111, 120–124.10.1016/j.ygyno.2008.06.03218692882
  9. Guzm an-Olea, E., Bermu dez-Morales, V. H., Peralta-Zaragoza, O., Torres-Poveda, K., Madrid-Marina, V. (2012). Molecular mechanism and potential targets for blocking HPV-induced lesion development. J. Oncol., 20, 278312.10.1155/2012/278312
  10. Kojima, S., Kawana, K., Tomio, K., Yamashita, A., Taguchi, A., Miura, S., Adachi, K., Nagamatsu, T., Nagasaka, K., Matsumoto, Y., et al. (2013). The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN. Amer. J. Reprod. Immunol., 69 (2), 134–141.10.1111/aji.1203023057776
  11. Loddenkemper, C., Hoffmann, C., Stanke, J., Nagorsen, D., Baron, U., Olek, S., Huehn, J., Ritz, J. P., Stein, H., Kaufmann, A. M., Schneider, A., Cichon, C. (2009). Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci., 100 (6), 1112–1117.10.1111/j.1349-7006.2009.01153.x19514119
  12. Litwin, T. R., Irvin, S. R., Chornock, R. L., Sahasrabuddhe, V. V., Stanley, M., Wentzensen, N. (2021). Infiltrating T-cell markers in cervical carcinogenesis: A systematic review and meta-analysis. Brit. J. Cancer., 124 (4), 831–841.10.1038/s41416-020-01184-x788459233257839
  13. Martin, C. M., O’Leary, J. J., Phil, D. (2011). Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract. Res. Clin. Obstet. Gynaecol., 25, 605–615.10.1016/j.bpobgyn.2011.04.005
  14. Maskey, N., Thapa, N., Maharjan, M., Shrestha, G., Maharjan, N., Cai, H., Liu, S. (2019). Infiltrating CD4 and CD8 lymphocytes in HPV infected uterine cervical milieu. Cancer Manag Res., 14 (11), 7647-–7655.10.2147/CMAR.S217264669860431616181
  15. Molina, M. A., Carosi Diatricch, L., Castany Quintana, M., Melchers, W. J., Andralojc, K. M. (2020). Cervical cancer risk profiling: Molecular biomarkers predicting the outcome of hrHPV infection. Expert Rev. Mol. Diagn., 20 (11), 1099–1120.10.1080/14737159.2020.183547233044104
  16. Monnier-Benoit, S., Mauny, F., Riethmuller, D., Guerrini, J. S., Cãpîlna, M., Félix, S., Seillès, E., Mougin, C., Prétet, J. L. (2006). Immunohisto-chemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol Oncol., 102 (1), 22–31.10.1016/j.ygyno.2005.11.03916427684
  17. Nguyen, H. H., Broker, T. R., Chow, L. T., Alvarez, R. D., Vu, H. L., Andrasi, J., Brewer, L. R., Jin, G., Mestecky, J. (2005). Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol., 96 (2), 452–461.10.1016/j.ygyno.2004.10.01915661235
  18. Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., Woller, N. (2018). CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol. Life Sci., 75, 689.10.1007/s00018-017-2686-7576982829032503
  19. Øvestad, I. T., Gudlaugsson, E., Skaland, I., Malpica, A., Kruse, A. J., Janssen, E. A, Baak, J. P. (2010). Local immune response in the micro-environment of CIN2-3 with and without spontaneous regression. Mod. Pathol., 23 (9),1231–1240.10.1038/modpathol.2010.10920512116
  20. Ozaki, S., Zen, Y., Inoue, M. (2011). Biomarker expression in cervical intraepithelial neoplasia: Potential progression predictive factors for low-grade lesions. Hum. Pathol., 42,1007–1012.10.1016/j.humpath.2010.10.02121315414
  21. Shang, B., Liu, Y., Jiang, S. J., Liu, Y (2015). Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep., 5,15179.10.1038/srep15179460447226462617
  22. Shibata, T., Lieblong, B. J., Sasagawa, T., Nakagawa, M. (2019). The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treatment Rev., 10, 1016.10.1016/j.ctrv.2019.07.001671012331302573
  23. Schorge, J. O., Lea, J. S., Elias, K. J., Rajanbabu, R., Coleman, R. L., Miller, D. S., Ashfaq, R. (2004). p16 as a molecular biomarker of cervical adenocarcinoma. Amer. J. Obstet. Gynecol., 190, 668–673.10.1016/j.ajog.2003.09.03815041997
  24. Tainio, K., Athanasiou, A., Tikkinen, K. A. O., Aaltonen, R., Cárdenas, J., Hernándes Glazer-Livson, S., Jakobsson, M., Joronen, K., Kiviharju, M., et al. (2018). Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: Systematic review and meta-analysis. Brit. Med. J., 360, k499.10.1136/bmj.k499582601029487049
  25. Trifonova, R. T., Lieberman. J., van Baarle, D. (2014). Distribution of immune cells in the human cervix and implications for HIV transmission. Amer. J. Reprod. Immunol., 71 (3), 252–64.10.1111/aji.12198394353424410939
  26. Van Niekerk, D., Guillaud, M., Matisic, J., Benedet, J. L., Freeberg, J. A., Follen, M., MacAulay, C. (2007). p16 and MIB1improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: Methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing. Gynecol. Oncol., 107, S233–240.10.1016/j.ygyno.2007.07.064
  27. Vattai, A., Kremer, N., Meister, S., Beyer, S., Keilmann, L., Hester, A., Temelkov, M., Heidegger, H., Schmoeckel, E., Kessler, M., Mahner, S., Jeschke, U., Hertlein, L., Kolben, T. (2021). Role of FoxP3-positive regulatory T cells in regressive and progressive cervical dysplasia. J. Cancer Res. Clin. Oncol., 148 (2), 377–386. doi: 10.1007/s00432-021-03838-6.10.1007/s00432-021-03838-634739585
  28. Weston, G., Dombrowski, C., Harvey, M. J., Iftner, T., Kyrgiou, M., Founta, C., Adams, E. J. (2020). Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: A decision tree model based economic evaluation. BMJ Open, 10 (3), e031303.10.1136/bmjopen-2019-031303706407132152154
  29. Zheng, Hu., Ding, Ma. (2018). The precision prevention and therapy of HPV-related cervical cancer: New concepts and clinical implications. Cancer Med., 7 (10), 5217–5236.10.1002/cam4.1501
  30. Yang, H., Ye, S., Goswami, S., Li, T., Wu, J., Cao, C., Ma, J., Lu, B., Pie, X., Chen, Y., Yu, J., Xu, H., Qiu, L., Afridi, S., Xiang, L., Zhang, X. (2020). Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma. Int. J. Cancer, 146 (7), 1993–2006.10.1002/ijc.3278231709528
DOI: https://doi.org/10.2478/prolas-2022-0033 | Journal eISSN: 2255-890X | Journal ISSN: 1407-009X
Language: English
Page range: 218 - 224
Submitted on: Dec 24, 2020
|
Accepted on: Jan 10, 2022
|
Published on: Jun 2, 2022
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2022 Androniks Mitiļdžans, Tatjana Zablocka, Sergejs Isajevs, Valentīna Gordjušina, Dace Rezeberga, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.